Immupharma PLC CANCER UPDATE: IPP-204106 (6464E)

TIDMIMM

RNS Number : 6464E

Immupharma PLC

11 February 2015

 
 FOR IMMEDIATE RELEASE   11 FEBRUARY 2015

CANCER UPDATE: IPP-204106

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides an update on its lead Cancer programme - IPP-204106.

As previously stated, the Phase I/IIa clinical trial with the next generation "polyplexed Nucant" formulation taking place in three European hospitals including the prestigious Institute Jules Bordet in Belgium, has been completed.

This Phase I/IIa study was a dose-finding adaptive study where the Nucant was associated with chondroitin sulfate, which has shown in preclinical studies a strong potentiating effect of the Nucant. The results demonstrate that the maximum tolerated dose with chondroitin sulfate was 9mg/kg. This was the primary objective of the study.

In preclinical studies it was indicated that a 1mg/kg equivalent human dose with chondroitin sulfate in a combination therapy using the cancer drug Gemcitabin demonstrated a massive reduction in tumour volume in mouse pancreatic cancer.

These Phase I/IIa results now allow ImmuPharma, from a regulatory perspective, to commence a Phase II study in pancreatic cancer using the optimum human dosage.

A further update on this new Phase II study will be given in due course.

-Ends-

For further information please contact:

 
                                        + 44 (0) 20 7152 
 ImmuPharma plc                                     4080 
 Dimitri Dimitriou, Chief 
  Executive Officer 
 Dr Robert Zimmer, President 
  and Chief Scientific Officer 
 Richard Warr, Chairman 
 Lisa Baderoon, Head of Investor 
  Relations                         + 44 (0) 7721 413496 
 
 Panmure, Gordon & Co., NOMAD 
  & Broker                          +44 (0) 20 7886 2500 
 Hugh Morgan, Fred Walsh, 
  Duncan Monteith

This information is provided by RNS

The company news service from the London Stock Exchange

END

STREAAAFFEFSEFF

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024